- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CARsgen Therapeutics: CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology | 34 | PR Newswire | SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 06.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT UPDATED RESEARCH RESULTS OF CT0596 AT ASH 2025 ANNUAL CONGRESS | 1 | HKEx | ||
| 24.09. | CARSGEN-B (02171): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.09. | CARSGEN-B (02171): PASSING AWAY OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 18.09. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME | 2 | HKEx | ||
| 18.09. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL AT 22ND IMS ANNUAL MEETING OF 2025 | - | HKEx | ||
| 04.09. | CARSGEN-B (02171): INTERIM REPORT 2025 | 1 | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.09. | CARSGEN-B (02171): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | - | HKEx | ||
| 15.08. | CARsgen Therapeutics Holdings reports H1 results | 3 | Seeking Alpha | ||
| 15.08. | CARsgen Therapeutics Announces 2025 Interim Results | 455 | PR Newswire | SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| 14.08. | CARSGEN-B (02171): ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT ... | 2 | HKEx | ||
| 01.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 1 | HKEx | ||
| 25.07. | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 1 | HKEx | ||
| 22.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL FOR ADJUVANT THERAPY OF PANCREATIC CANCER ACCEPTED FOR POSTER PRESENTATION ... | 2 | HKEx | ||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL ... | 2 | HKEx | ||
| 16.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON CT071 AT 2025 EHA ANNUAL CONGRESS | 3 | HKEx | ||
| 02.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON SATRI-CEL IN THE LANCET AND AT THE 2025 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 28.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SATRICABTAGENE AUTOLEUCEL GRANTED PRIORITY REVIEW BY THE NMPA | 1 | HKEx | ||
| 22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2025 | - | HKEx | ||
| 13.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 2 | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 49,740 | -2,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen |
CARSGEN THERAPEUTICS HOLDINGS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.